Literature DB >> 6236286

A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia.

N Quinn, C D Marsden.   

Abstract

Eleven patients with Huntington's disease and nine patients with tardive dyskinesia participated in a randomised double-blind crossover trial of sulpiride (as sole antidopaminergic therapy) versus placebo. Although functional improvement was not seen in Huntington's disease patients, sulpiride reduced movement count and total dyskinesia score in both conditions. Sulpiride differs pharmacologically in several respects from conventional neuroleptics, and has not been convincingly shown to cause tardive dyskinesia. Among currently available treatments, it may therefore be considered a drug of choice for treatment of tardive dyskinesia.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6236286      PMCID： PMC1027949          DOI： 10.1136/jnnp.47.8.844

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  10 in total

1.  Huntington disease: clinical care and evaluation.

Authors:  I Shoulson; S Fahn
Journal:  Neurology       Date:  1979-01       Impact factor: 9.910

Review 2.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

3.  Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration.

Authors:  A Clow; A Theodorou; P Jenner; C D Marsden
Journal:  Eur J Pharmacol       Date:  1980-05-02       Impact factor: 4.432

4.  Tiapride in the treatment of Huntington's chorea.

Authors:  R A Roos; O J Buruma; G W Bruyn; B Kemp; E A van der Velde
Journal:  Acta Neurol Scand       Date:  1982-01       Impact factor: 3.209

Review 5.  Assessment of extrapyramidal disorders.

Authors:  C D Marsden; M Schachter
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

6.  Tardive dyskinesia associated with metoclopramide.

Authors:  S Lavy; E Melamed; S Penchas
Journal:  Br Med J       Date:  1978-01-14

7.  Controlled trial of sulpiride in chronic schizophrenic patients.

Authors:  J G Edwards; J R Alexander; M S Alexander; A Gordon; T Zutchi
Journal:  Br J Psychiatry       Date:  1980-12       Impact factor: 9.319

8.  The role of D-1 and D-2 receptors.

Authors:  M Schachter; P Bédard; A G Debono; P Jenner; C D Marsden; P Price; J D Parkes; J Keenan; B Smith; J Rosenthaler; R Horowski; R Dorow
Journal:  Nature       Date:  1980-07-10       Impact factor: 49.962

9.  Metoclopramide-induced Parkinsonism. Clinical characteristics of ten cases.

Authors:  T Indo; K Ando
Journal:  Arch Neurol       Date:  1982-08

10.  Sulpiride in tardive dyskinesia.

Authors:  D E Casey; J Gerlach; H Simmelsgaard
Journal:  Psychopharmacology (Berl)       Date:  1979       Impact factor: 4.530
  10 in total
  21 in total

1.  Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.

Authors:  J P van Vugt; S Siesling; M Vergeer; E A van der Velde; R A Roos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

Review 2.  Antipsychotic medication for elderly people with schizophrenia.

Authors:  R G Marriott; W Neil; S Waddingham
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

Review 3.  Do neuroleptic drugs still have a place in neurological therapy?

Authors:  T Klockgether; J Dichgans
Journal:  J Neurol       Date:  1990-07       Impact factor: 4.849

4.  Tiapride in 12 Huntington's disease patients.

Authors:  N Quinn; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-03       Impact factor: 10.154

Review 5.  Dopamine and glutamate in Huntington's disease: A balancing act.

Authors:  Véronique M André; Carlos Cepeda; Michael S Levine
Journal:  CNS Neurosci Ther       Date:  2010-04-08       Impact factor: 5.243

Review 6.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

Review 7.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

Review 8.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 9.  Advances in the pharmacological management of Huntington's disease.

Authors:  Samuel Frank; Joseph Jankovic
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

10.  Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia.

Authors:  U Andersson; J E Häggström; M I Nilsson; E Widerlöv
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.